CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Rotavirus Infections
Interventions
BIOLOGICAL

3.75 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)

CDC-9 IRV adjuvanted with alhydrogel for IM administration in 0.5 mL is comprised of single human rotavirus for protection against rotavirus infection

BIOLOGICAL

7.5 µg Dose of CDC-9 Inactivated Rotavirus Vaccine (IRV)

CDC-9 IRV adjuvanted with alhydrogel for IM administration in 0.5 mL is comprised of single human rotavirus for protection against rotavirus infection

OTHER

Placebo

0.5 mL sterile saline administered via IM injection

Trial Locations (1)

30322

Emory Children's Center - Vaccine Research Clinic, Atlanta

All Listed Sponsors
collaborator

Emory-Children's Center

OTHER

collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

Children's Hospital Medical Center, Cincinnati

OTHER

lead

Centers for Disease Control and Prevention

FED

NCT06485258 - CDC-9 Inactivated Rotavirus Vaccine (IRV) Intramuscular (IM) Phase 1 Clinical Trial in Healthy Adults | Biotech Hunter | Biotech Hunter